Agenus Inc. (AGEN) Receives Consensus Rating of “Hold” from Analysts
Shares of Agenus Inc. (NASDAQ:AGEN) have been given a consensus rating of “Hold” by the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $6.33.
AGEN has been the topic of a number of recent analyst reports. BidaskClub downgraded shares of Agenus from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. ValuEngine raised shares of Agenus from a “strong sell” rating to a “sell” rating in a report on Monday, July 24th. Jefferies Group LLC reissued a “buy” rating and issued a $7.00 price target on shares of Agenus in a report on Friday, August 4th. Finally, Zacks Investment Research raised shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Wednesday, July 5th.
Agenus (AGEN) opened at 4.10 on Friday. The firm has a 50-day moving average of $3.84 and a 200 day moving average of $3.85. The company’s market capitalization is $408.82 million. Agenus has a 12-month low of $3.20 and a 12-month high of $7.49.
Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.32) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.04. The business had revenue of $4.21 million for the quarter, compared to the consensus estimate of $6.66 million. Agenus had a negative net margin of 280.96% and a negative return on equity of 37,577.49%. The company’s revenue was down 36.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.33) earnings per share. Analysts expect that Agenus will post ($1.13) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/23/agenus-inc-agen-receives-consensus-rating-of-hold-from-analysts.html.
Institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC lifted its holdings in shares of Agenus by 175.7% in the first quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock worth $140,000 after buying an additional 23,689 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Agenus by 12.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 55,920 shares of the biotechnology company’s stock worth $211,000 after buying an additional 6,101 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Agenus by 3,447.2% in the first quarter. Goldman Sachs Group Inc. now owns 673,333 shares of the biotechnology company’s stock worth $2,539,000 after buying an additional 654,351 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Agenus by 1.9% in the first quarter. Wells Fargo & Company MN now owns 466,799 shares of the biotechnology company’s stock worth $1,759,000 after buying an additional 8,921 shares in the last quarter. Finally, KCG Holdings Inc. lifted its holdings in shares of Agenus by 200.8% in the first quarter. KCG Holdings Inc. now owns 75,453 shares of the biotechnology company’s stock worth $284,000 after buying an additional 50,373 shares in the last quarter. 39.51% of the stock is currently owned by hedge funds and other institutional investors.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.